Edition:
United States

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

1.91USD
22 Sep 2017
Change (% chg)

$0.03 (+1.60%)
Prev Close
$1.88
Open
$1.91
Day's High
$1.95
Day's Low
$1.89
Volume
14,041
Avg. Vol
29,060
52-wk High
$3.67
52-wk Low
$0.49

Chart for

About

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally... (more)

Overall

Beta: 2.61
Market Cap(Mil.): $66.95
Shares Outstanding(Mil.): 35.05
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.89 16.34
EPS (TTM): -- -- --
ROI: -- 3.08 14.66
ROE: -- 4.82 14.00

BRIEF-Galectin Therapeutics Q2 loss per share $0.14

* Galectin Therapeutics reports 2017 second quarter financial results and provides business update

Aug 14 2017

BRIEF-Galectin Therapeutics updates on completion of Nash Cx trial

* Galectin therapeutics announces important milestones towards completion of Nash Cx trial

Jun 13 2017

BRIEF-Galectin Therapeutics Q1 loss per share $0.15

* Galectin therapeutics reports 2017 first quarter financial results and provides business update

May 15 2017

BRIEF-Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

* Galectin Therapeutics receives notice of Japanese decision to grant a composition of matter patent for GR-MD-02

Apr 25 2017

BRIEF-Galectin Therapeutics says co had $15.4 mln of non-restricted cash and cash equivalents as of December 31 2016

* Galectin Therapeutics Inc - as of December 31, 2016, company had $15.4 million of non-restricted cash and cash equivalents - sec filing

Mar 28 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.45 +0.50
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Roche Holding Ltd. (ROG.S) CHF248.00 -1.00
Roche Holding Ltd. (RO.S) CHF248.00 -1.00
Eli Lilly and Co (LLY.N) $83.91 +0.58
Momenta Pharmaceuticals, Inc. (MNTA.OQ) $17.15 +0.35

Earnings vs. Estimates